



Roche Announces New Five-Year Data of Polivy for Previously Untreated Diffuse Large B-cell Lymphoma

TOKYO, December 9, 2024 -- [Chugai Pharmaceutical Co., Ltd.](#) (TOKYO: 4519) announced that Roche issued a press release on December 8, regarding five-year data from POLARIX study of Polivy® (generic name: polatuzumab vedotin) for previously untreated diffuse large B-cell lymphoma (DLBCL). The data was presented at the 66th American Society of Hematology (ASH) Annual Meeting.

Please refer to the link below for details of the press release:

Five-year results confirm Roche's Polivy combination therapy as new standard of care for previously untreated aggressive lymphoma

<https://www.roche.com/media/releases/med-cor-2024-12-08>

Trademarks used or mentioned in this release are protected by laws.

###